Open-label, dose escalation phase 1 clinical trial of AlphaMedixTM for targeted alpha emitter therapy in adult patients with differentiated neuroendocrine tumors.

Trial Profile

Open-label, dose escalation phase 1 clinical trial of AlphaMedixTM for targeted alpha emitter therapy in adult patients with differentiated neuroendocrine tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs 212-Pb-AR-RMX (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 10 Jan 2018 According to a RadioMedix media release, patients will be enrolled at Excel Diagnostic and Nuclear Oncology Center (Houston, TX).
    • 10 Jan 2018 Status changed from planning to recruiting, according to a RadioMedix media release.
    • 03 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top